What are the new prescription rules?

New federal rules from the U.S. Department of Health and Human Services (HHS) give doctors and patients real-time access to drug prices, out-of-pocket costs, and prior authorization requirements through certified electronic health systems.

Because prescription rules vary widely depending on your location, specific medications, and insurance, here is a breakdown of key recent national updates and standard guidelines:

Real-Time Cost and Prior Authorization Transparency

• HHS and ASTP/ONC Rule: This standard gives healthcare providers direct visibility into a patient’s specific insurance coverage (Medicare Part D, Medicaid, and commercial plans) during a visit.
• Benefits: Doctors can see lower-cost alternatives instantly and streamline electronic prior authorizations to reduce delays.

Controlled Substance and General Refill Rules

• Refill Limits: Non-controlled medications generally allow refills for up to one year depending on the prescription, while Schedule III-IV controlled substances are typically capped at 5 refills or 6 months. Schedule II drugs (such as strong opioids) do not allow any refills and require a new written prescription each time.
• Early Refills: Many insurance plans allow standard non-controlled medication refills when 75% of the previous supply has been used (about 7 days early for a 30-day supply). Controlled substances often have stricter state or pharmacy limits, commonly requiring at least 28 days to pass between 30-day fills.
• Telehealth Rules: Prescribing controlled substances via telehealth often requires an in-person medical evaluation first, subject to specific regional or temporary federal flexibilities.

Note: If you are referring to a specific international rule—such as New Zealand's policy change extending standard stable chronic condition prescriptions to 12 months—or a specific state regulation, check with your local pharmacist or healthcare provider for exact compliance requirements in your area.

You can typically refill a controlled substance prescription only 1 to 2 days early, or around day 28 of a standard 30-day supply.

Refill Timing and Rules

• Schedule II drugs (such as Adderall, oxycodone, and Ritalin) cannot be refilled under federal law. You need a new prescription each month, and pharmacies usually wait until day 28, 29, or 30 from your last pickup date to dispense it.
• Schedules III through V drugs (such as Xanax, Valium, or specific cough syrups) allow limited refills, but insurance plans and pharmacies often enforce an 85% use rule, meaning you must wait until you have used 85% to 90% of your current pills.

Factors That Affect Timing

• Insurance policies: Your insurance company sets a "refill too soon" limit that dictates when they will pay for the medication.
• State laws: Individual state regulations can be stricter than general guidelines.
• Pharmacist discretion: Pharmacists have the legal right to delay a fill based on professional judgment, safety, or review of your state's Prescription Drug Monitoring Program (PDMP) history.

Exceptions for Early Pickups

• Travel: You can request a vacation override through your doctor and insurance provider if you will be gone for an extended period.
• Dosage changes: If your doctor increases your daily dose, a new prescription or adjustment override is required.
• Lost or stolen medication: Most plans require special documentation or police reports, and approval is never guaranteed.

Several major brand-name drugs are losing patent exclusivity or seeing their first generic approvals and market launches in 2026.

Key Medications Slated for Generic or Biosimilar Availability in 2026

• Januvia (sitagliptin) and Janumet (sitagliptin/metformin): Merck's blockbuster diabetes medications face generic competition following patent and litigation settlements.
• Farxiga (dapagliflozin): The FDA approved the First Generic Drug Approvals for dapagliflozin tablets in April 2026.
• Pomalyst (pomalidomide): Bristol Myers Squibb's multiple myeloma drug faces expected generic market entries in 2026.
• Xtandi (enzalutamide): Generic enzalutamide received final FDA approval in early 2026 for commercial rollout.
• Xolair (omalizumab): Biosimilar competition for Roche's biologic asthma and allergy treatment is expected to launch in the second half of 2026.
• Brilinta (ticagrelor): Slated for generic market transition during 2026.
• Entresto (sacubitril/valsartan): Novartis faces patent expirations for this crucial heart-failure medication.

(Note: For high-demand medications like Ozempic/Wegovy [semaglutide] or Mounjaro/Zepbound [tirzepatide], true FDA-approved retail generics are delayed due to complex device and secondary patent layering well into the future, meaning current low-cost alternatives are typically unregulated compounded peptides rather than official generics.) You can review a broader tracking list via Drugs.com Generic Approvals.

There is no single "new prescription law," but rather several major federal and state changes taking effect in 2026 regarding drug pricing, Medicare, and import rules.

Medicare Price Caps and Negotiations

• Lowered Out-of-Pocket Costs: Medicare Part D out-of-pocket costs are capped at $2,100 for beneficiaries.
• Negotiated Drug Prices: The first round of lower, government-negotiated prices for 10 high-cost Medicare medications (such as Eliquis, Jardiance, and Januvia) officially went into effect, saving billions.

Medicaid Most-Favored-Nation Pricing

• State Rebates: The administration announced that all 50 state Medicaid programs will benefit from agreements requiring drug makers to match the lowest prices paid by other developed nations (most-favored-nation pricing) via increased manufacturer rebates.

Customs and Import Changes

• Import Restrictions: A suspension of the $800 customs exemption requires formal entry bonds for mailed imports, which critics and lawmakers warn may restrict individuals from buying low-cost personal prescription drugs from Canada and overseas.

Telehealth Flexibilities

• Controlled Substances: Federal telemedicine flexibilities allowing authorized medical providers to prescribe controlled substances via telehealth without an initial in-person exam remain extended through December 31, 2026.

Prescription drug prices are being reduced significantly through the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.

2026 Price Reductions

Price reductions for the first 10 selected Medicare Part D drugs took effect on January 1, 2026, with discounts ranging from 38% to 79%:

• Januvia & Fiasp (79% discount)
• Farxiga (76% discount)
• NovoLog (68% discount)
• Enbrel (67% discount)
• Jardiance & Stelara (66% discount)
• Xarelto (62% discount)
• Eliquis (56% discount)
• Entresto (53% discount)
• Imbruvica (38% discount)

Additionally, under inflation-limit rules, dozens of Medicare Part B prescription drugs periodically receive lower coinsurance rates when manufacturer price hikes exceed the inflation rate.

Upcoming 2027 Price Reductions

Negotiated prices for an additional 15 blockbuster drugs will take effect on January 1, 2027, saving billions of dollars:

• Ozempic & Wegovy (reduced from $959 to $274 per 30-day supply)
• Pomalyst (reduced from $21,744 to $8,650)
• Trelegy Ellipta, Xtandi, Ofev, Ibrance, Linzess, Calquence, Austedo, Breo Ellipta, Xifaxan, Vraylar, Tradjenta, Janumet, and Otezla